2020
DOI: 10.1016/j.antiviral.2020.104757
|View full text |Cite
|
Sign up to set email alerts
|

Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 25 publications
0
8
0
Order By: Relevance
“…Although the half-life of the antibody in mouse and cynomolgus monkeys may differ, these results still suggest that hu1-23 may clear the HBsAg much more efficacy. PK studies showed that hu1-23 has a shorter half-life in cynomolgus monkeys than that of hu3-23 and huE6F6-1 [ 13 ]. It would be interesting to engineer hu1-23 with an enhanced half-life, pH-dependent-HBsAg binding and improve therapeutic potency.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Although the half-life of the antibody in mouse and cynomolgus monkeys may differ, these results still suggest that hu1-23 may clear the HBsAg much more efficacy. PK studies showed that hu1-23 has a shorter half-life in cynomolgus monkeys than that of hu3-23 and huE6F6-1 [ 13 ]. It would be interesting to engineer hu1-23 with an enhanced half-life, pH-dependent-HBsAg binding and improve therapeutic potency.…”
Section: Discussionmentioning
confidence: 99%
“…Although our previous studies have confirmed that E6F6 and its humanized antibodies are effective in HBV suppression [ 13 ], more candidate antibody molecules with comparable or even better functions are needed as backups [ 31–33 ]. Therefore, hu1-23 and hu3-23 are novel antibodies that may serve as anti-HBsAg therapeutic candidates for CHB patients.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…In vitro affinity is needed when the affinity of antibodies generated by these methods does not meet the requirement for drug development. Moreover, to reduce their antigenicity, humanization of antibodies generated from non-humanized animals frequently results in reduction of antibody affinity, which has to be restored [31]. The display methods mentioned above can be used for in vitro affinity maturation, and successful applications have been reported [32].…”
Section: In Vitro Maturation Of Therapeutic Antibodiesmentioning
confidence: 99%